China Enhances Dope Management And ADR Systems
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China will forbid pharmaceutical and chemical companies in China from manufacturing, selling, trading, exporting and importing any anabolic agents without the government approval, and China's State FDA will improve the adverse drug reaction report system, SFDA said at a July 8 press conference
You may also be interested in...
Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec
SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference
Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec
SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference
China Implements Credit Ratings System for Drug Advertising
SHANGHAI - China's State Food and Drug Administration announced Nov. 8 that it will implement new credit management measures to clamp down on illegal advertising of drugs, medical devices and health supplements